• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Sunovion Pharmaceuticals

edit

Sunovion Pharmaceuticals Inc. engages in discovering, developing, and commercializing therapeutic products for patients suffering from central nervous system disorders, respiratory disorders, and other illnesses. Its products include LUNESTA medicine that helps people sleep better; XOPENEX levalbuterol HCl inhalation solution; and BROVANA aformoterol tartrate inhalation solution. The company’s products also comprise OMNARIS ciclesonide nasal spray; ALVESCO ciclesonide HFA inhalation aerosol; and LATUDA, an oral antipsychotic tablet for the treatment of schizophrenia. It offers products for the treatment of depression, epilepsy, neuropathic pain, and insomnia, as well as respiratory conditions, such as asthma, allergic rhinitis, and chronic obstructive pulmonary diseases. Sunovion Pharmaceuticals Inc. was formerly known as Sepracor, Inc. and changed its name in October 2010. The company was founded in 1984 and is headquartered in Marlborough, Massachusetts. As of October 20, 2009, Sunovion Pharmaceuticals Inc. operates as a subsidiary of Dainippon Sumitomo Pharma America Holdings, Inc.

Recent Milestones

edit

• 
  Sunovion Pharmaceuticals acquired Elevation Pharmaceuticals for $430M. (8/30/12)
  Posted 8/30/12 at 7:34pm via dowjones.com
• 
  Sunovion Pharmaceuticals added Mark Iwicki as President & CEO.
  Posted 8/24/11 at 6:23pm
• 
  Sunovion Pharmaceuticals added Jolene L. Varney as Senior Vice President and CFO.
  Posted 8/24/11 at 6:23pm

Videos

Screenshots

edit

Sources

1. Investors Cash In as Sunovion Acquires Elevation Pharmaceuticals (pevc.dowjones.com) [edit]